Related references
Note: Only part of the references are listed.Are Chronic Myeloid Leukemia Patients More at Risk for Second Malignancies? A Population-based Study
Paola Rebora et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2010)
Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation
Paul J. Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
Hugues de Lavallade et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment
Andreas Hochhaus et al.
BLOOD (2008)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center -: A 4.5-year follow-up
T Lahaye et al.
CANCER (2005)
Gynaecomastia in men with chronic myeloid leukaemia after imatinib
C Gambacorti-Passerini et al.
LANCET (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
CB Gambacorti-Passerini et al.
LANCET ONCOLOGY (2003)
Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation
TL Kiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Detection and quantification of residual disease in chronic myelogenous leukemia
A Hochhaus et al.
LEUKEMIA (2000)
Share Paper
